Log in

NASDAQ:CRTXCortexyme Stock Price, Forecast & News

$42.18
-2.05 (-4.63 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$42.10
Now: $42.18
$45.08
50-Day Range
$39.44
MA: $47.05
$56.48
52-Week Range
$19.35
Now: $42.18
$73.84
Volume226,400 shs
Average Volume202,511 shs
Market Capitalization$1.24 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.30 per share

Profitability

Net Income$-36,980,000.00

Miscellaneous

Employees16
Market Cap$1.24 billion
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 13.9% and is now trading at $42.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cortexyme.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cortexyme.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.16. View Cortexyme's earnings history.

What price target have analysts set for CRTX?

2 Wall Street analysts have issued 12-month target prices for Cortexyme's stock. Their forecasts range from $59.00 to $70.00. On average, they expect Cortexyme's share price to reach $64.50 in the next year. This suggests a possible upside of 52.9% from the stock's current price. View analysts' price targets for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

Headlines about CRTX stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCortexyme.

Are investors shorting Cortexyme?

Cortexyme saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,060,000 shares, an increase of 21.2% from the April 30th total of 1,700,000 shares. Based on an average daily volume of 129,300 shares, the days-to-cover ratio is presently 15.9 days. Approximately 17.4% of the shares of the company are sold short. View Cortexyme's Current Options Chain.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), AT&T (T), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Thermo Fisher Scientific (TMO) and Home Depot (HD).

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (8.64%), Capital International Investors (3.35%), Capital World Investors (2.53%), BlackRock Inc. (2.22%), State Street Corp (0.66%) and Geode Capital Management LLC (0.46%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc. View institutional ownership trends for Cortexyme.

Which institutional investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Invesco Ltd., Alps Advisors Inc., Virtus ETF Advisers LLC, Alliancebernstein L.P., UBS Group AG, Legal & General Group Plc, and American International Group Inc.. View insider buying and selling activity for Cortexyme.

Which institutional investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Pacific Heights Asset Management LLC, Capital Research Global Investors, BlackRock Inc., Capital International Investors, Geode Capital Management LLC, Ikarian Capital LLC, and State Street Corp. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc. View insider buying and selling activity for Cortexyme.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $42.18.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.24 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.